Selecting First-Line Therapy in Gastric Cancers: A Biomarker-Driven Approach
Update: 2025-11-10
Description
Host: Jennifer Caudle, DO
Guest: Samuel Klempner, MD
Guest: Nataliya Uboha, MD, PhD
Guest: Samuel Klempner, MD
Guest: Nataliya Uboha, MD, PhD
Testing for biomarkers like PD-L1, HER2, claudin 18.2, and FGFR2b is reshaping our approach to first-line therapy in advanced gastric and gastroesophageal junction cancers. Alongside biomarker profiling, we must also weigh practical considerations around efficacy, toxicity, and patient-specific factors when selecting treatment. Joining Dr. Jennifer Caudle to explore how we can optimize our first-line treatment selection are Drs. Samuel Klempner and Dr. Nataliya Uboha. Dr. Klempner is an Associate Professor of Medicine at Harvard Medical School, and Dr. Uboha is an Associate Professor in the Division of Hematology and Oncology in the Department of Medicine at the University of Wisconsin.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
